Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 10;37(32):3018-3031.
doi: 10.1200/JCO.19.00738. Epub 2019 Sep 26.

Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study

Wassim Chemaitilly  1 , Qi Liu  2 , Laura van Iersel  1 , Kirsten K Ness  1 , Zhenghong Li  1 , Carmen L Wilson  1 , Tara M Brinkman  1 , James L Klosky  3 , Nicole Barnes  1 , Karen L Clark  1 , Rebecca M Howell  4 , Susan A Smith  4 , Matthew J Krasin  1 , Monika L Metzger  1 , Gregory T Armstrong  1 , Michael W Bishop  1 , Hanneke M van Santen  5 , Ching-Hon Pui  1 , Deo Kumar Srivastava  1 , Yutaka Yasui  1 , Melissa M Hudson  1 , Leslie L Robison  1 , Daniel M Green  1 , Charles A Sklar  6
Affiliations

Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study

Wassim Chemaitilly et al. J Clin Oncol. .

Abstract

Purpose: Direct assessment of Leydig cell function in childhood cancer survivors has been limited. The objectives of this study were to describe the prevalence of and risk factors for Leydig cell failure (LCF), Leydig cell dysfunction (LCD), and associated adverse health outcomes.

Patients and methods: In this retrospective study with cross-sectional health outcomes analysis, we evaluated 1,516 participants (median age, 30.8 years) at a median of 22.0 years after cancer diagnosis. LCF was defined as serum total testosterone less than 250 ng/dL (or 8.67 nmol/L) and luteinizing hormone greater than 9.85 IU/L, and LCD by testosterone as 250 ng/dL or greater and luteinizing hormone greater than 9.85 IU/L. Polytomous logistic regression evaluated associations with demographic and treatment-related risk factors. Log-binomial regression evaluated associations with adverse physical and psychosocial outcomes. Piecewise exponential models assessed the association with all-cause mortality.

Results: The prevalence of LCF and LCD was 6.9% and 14.7%, respectively. Independent risk factors for LCF included an age of 26 years or older at assessment, testicular radiotherapy at any dose, and alkylating agents at cyclophosphamide equivalent doses of 4,000 mg/m2 or greater. The risk increased with older age, higher doses of testicular radiotherapy, and cyclophosphamide equivalent doses. LCF was significantly associated with abdominal obesity, diabetes mellitus, erectile dysfunction, muscle weakness, and all-cause mortality. LCD was associated with unilateral orchiectomy and the same risk factors as LCF; no significant associations were found with adverse physical or psychosocial outcomes.

Conclusion: Older age, testicular radiotherapy, and exposure to alkylating agents were associated with LCF, which was associated with adverse physical and psychosexual outcomes. LCD, although having similar risk factors, was not associated with adverse health outcomes. Additional studies are needed to investigate the role of sex hormone replacement in mitigating the burden from adverse outcomes in survivors.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Flow diagram. FSH, follicle-stimulating hormone; LCD, Leydig cell dysfunction; LCF, Leydig cell failure; LH, luteinizing hormone.
See this image and copyright information in PMC

References

    1. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 109:djx030. 2017 - PMC - PubMed
    1. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: Life-long risks and responsibilities. Nat Rev Cancer. 2014;14:61–70. - PMC - PubMed
    1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–1582. - PubMed
    1. Ness KK, Krull KR, Jones KE, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: A report from the St Jude Lifetime cohort study. J Clin Oncol. 2013;31:4496–4503. - PMC - PubMed
    1. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32:1218–1227. - PMC - PubMed

Publication types